ECE2017 Eposter Presentations: Environment, Society and Governance Diabetes complications (2 abstracts)
1Belarusian State Medical University, Minsk, Belarus; 231th city polyclinic in Minsk, Minsk, Belarus.
Background and aims: According to current recommendations of the American Diabetes Association expedient screening of microvascular complications in all patients with type 1 diabetes (T1D) with a duration of 5 years of the disease. Therefore, the aim of study was to assess the prevalence of microvascular complications in T1D patients aged 30−45 years with regard to the duration of the disease 5−10 years and over 10 years.
Materials and methods: We examined 360 patients with type 1 diabetes, 196 (54.4%) men and 164 (45.6%) women. The average age of the patients was 37.9±4.5 (37.4−38.4) years, the age of onset of diabetes 28.1±6.2 (27.5−28.8) years, duration of the disease 9.0 (7.0−12.0) years, BMI 24.8±3.95 (23.625.2) kg/m2, HbA1c 8.37±1.83 (8.18−8.56). In the study, carried out a detailed clinical examination of patients with medical records analysis.
Results: Diabetic peripheral neuropathy (DPN) was diagnosed in 133 (36.9%) patients; diabetic retinopathy (DR) − 78 (21.7%) patients, diabetic nephropathy (DN) − in 146 (40.6%) patients, albuminuria was detected in 137 (38.1%) persons. In general, microvascular complications of diabetes were set at 270 (75%) patients. With increasing duration of the disease for more than 10 years showed a significant increase in microvascular complications: DPN 30.6 vs 47.1% (χ2=9.91; P=0.002); DN − 34.2 vs 50.7% (χ2=9.60; P=0.002); albuminuria − 31.9 vs 47.8% (χ2=9.06; P=0.003); DR 40.1 vs 71.7% (χ2=34.2; P<0.005); any microvascular complications − 67.6 vs 86.9% (χ2=17.06; P<0,001). However, no significant differences in HbA1c: 8.32±1.83 vs 8.45±1.82% (P=0.539).
Conclusions: Patients with type 1 diabetes with disease duration 5−15 years microvascular complications recorded in 75% of cases. The increase in the prevalence of microvascular complications associated with the duration of the disease, but not with the level of HbA1c.